MedTrace Logo

Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer

NCT03766490 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2019-01-30

No results posted yet for this study

Summary

After the second-line treatment of patients with non-T790M mutations, chemotherapy with platinum-containing drugs was used, and chemotherapy-related toxicity was high. Studies have shown that bevacizumab combined with EGFR TKI have a good trend of benefit. This study is aimed to evaluate the efficacy and safety of Anlotinib Hydrochloride combined with first-generation EGFR TKIs as second-line treatment in advanced non-small cell lung cancer . The patients with IV non-small lung cancer have acquired resistance to prior first-generation EGFR TKIs and have non-T790M mutation.

Conditions

  • Non-Small-Cell Lung

Interventions

DRUG

Anlotinib Hydrochloride

Capsule, P.O. 12mg qd ,days 1-14, 21 days a cycle

DRUG

Gefitinib

Tablet, P.O. 250mg qd

DRUG

Icotinib

Tablet, P.O. 125mg tid

Sponsors & Collaborators

  • The First People's Hospital of Changzhou

    collaborator OTHER

  • Second Affiliated Hospital of Soochow University

    collaborator OTHER

  • Nantong University

    collaborator OTHER

  • Affiliated Hospital of Jiangnan University

    collaborator OTHER

  • Jiangyin People's Hospital

    collaborator OTHER

  • Changzhou No.2 People's Hospital

    collaborator OTHER

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

    collaborator INDUSTRY

  • The First Affiliated Hospital of Soochow University

    lead OTHER

Principal Investigators

  • Min Tao, Doctor · The First Affiliated Hospital of Soochow University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-30
Primary Completion
2019-12-20
Completion
2020-12-20

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03766490 on ClinicalTrials.gov